Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 3, 2014, Pages 309-313

  Berg, Inger Jorid ^a   Semb, Anne Grete ^a   van der Heijde, Désirée ^a,b   Kvien, Tore K ^a   Hisdal, Jonny ^c,d   Olsen, Inge C ^a   Dagfinrud, Hanne ^a   Provan, Sella A ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Ankylosing spondylitis; Cardiovascular disease; Disease activity; Hypertension; Uveitis

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PREVALENCE; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SMOKING; SYSTOLIC BLOOD PRESSURE; UVEITIS; COMPLICATION; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADULT; ATHEROSCLEROSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; UVEITIS;

EID: 84919638967     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.05.017     Document Type: Article

References (25)

1. Stolwijk C., van Tubergen A., Castillo-Ortiz J.D., Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2013 Sept 2, http://dx.doi.org/10.1136/annrheumdis.2013.203582 [E-pub ahead of print].
2. Brewerton D.A., Caffrey M., Nicholls A., Walters D., James D.C. Acute anterior uveitis and HL-A 27. Lancet 1973, 302:994-996.
3. Zeboulon N., Dougados M., Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008, 67:955-959.
4. van der Horst-Bruinsma I.E., Nurmohamed M.T., Landewé R.B. Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am 2012, 38:523-538.
5. Bremander A., Petersson I.F., Bergman S., Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011, 63:550-556.
6. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
7. van der Heijde D., Lie E., Kvien T.K., Sieper J., Van den Bosch F., Listing J., et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:1811-1818.
8. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
9. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
10. Jones S.D., Porter J., Garrett S.L., Kennedy L.G., Whitelock H., Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI). J Rheumatol 1995, 22:1609.
11. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
12. Elswood J., Calin A., Berg C., Rogers F. Ankylosing spondylitis. Comparative analysis of Swedish (n = 780) and British (n = 1500) experience-the National Ankylosing Spondylitis Societies. Scand J Rheumatol 1987, 16:437-440.
13. Chen C.H., Lin K.C., Chen H.A., Liao H.T., Liang T.H., Wang H.P., et al. Association of acute anterior uveitis with disease activity, functional ability and physical mobility in patients with ankylosing spondylitis: a cross-sectional study of Chinese patients in Taiwan. Clin Rheumatol 2007, 26:953-957.
14. Ward M.M., Weisman M.H., Davis J.C., Reveille J.D. Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 2005, 53:710-717.
15. Robertson L.P., Davis M.J. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology (Oxford) 2004, 43:1565-1568.
16. Loh A.R., Acharya N.R. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol 2010, 150:534-542.
17. Martin T.M., Rosenbaum J.T. An update on the genetics of HLA B27-associated acute anterior uveitis. Ocul Immunol Inflamm 2011, 19:108-114.
18. Sherlock J.P., Joyce-Shaikh B., Turner S.P., Chao C.C., Sathe M., Grein J., et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012, 18:1069-1076.
19. Panoulas V.F., Metsios G.S., Pace A.V., John H., Treharne G.J., Banks M.J., et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:1286-1298.
20. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
21. Innala L., Möller B., Ljung L., Magnusson S., Smedby T., Södergren A., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011, 13:R131.
22. Peters M.J., Symmons D.P., McCarey D., Dijkmans B.A., Nicola P., Kvien T.K., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
23. Canouï-Poitrine F., Lekpa F.K., Farrenq V., Boissinot V., Hacquard-Bouder C., Comet D., et al. Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey. Arthritis Care Res 2012, 64:919-924.
24. van Sijl A.M., van Eijk I., Peters M.J., Serne E.H., van der Horst-Bruinsma I.E., Smulders Y.M., et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis 2013 Oct 3, http://dx.doi.org/10.1136/annrheumdis.2013.203934 [E-pub ahead of print].
25. Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C., Leufkens H.G., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90:859-865.